Bezuclastinib
- Generic Name
- Bezuclastinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17N5O
- CAS Number
- 1616385-51-3
- Unique Ingredient Identifier
- 2ROQ545LAG
- Associated Conditions
- -
- Associated Therapies
- -
100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis
A 100-mg dose of bezuclastinib was safe and effective in improving symptoms and biomarkers for mast cell burden in non-advanced systemic mastocytosis patients, according to findings from the phase 2 Summit trial's open-label extension, presented at the 2024 ASH Annual Meeting. Bezuclastinib demonstrated rapid, deep, and sustained reductions in serum tryptase and significant improvements in symptom severity and quality of life over 24 weeks.
Early signs of efficacy for a novel drug and a new predictive tool to guide patient care
Dana-Farber researchers presented promising results at ASH for systemic mastocytosis, including bezuclastinib's efficacy and a mathematical model distinguishing disease forms.
Related Clinical Trials:
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial
Cogent Biosciences reports positive data from Phase 2 APEX trial on bezuclastinib for advanced systemic mastocytosis at ASH 2024, showing 52% ORR per mIWG criteria and 88% ORR per PPR criteria, with median time to response of 2.2 months. Top-line data from APEX Part 2 expected mid-2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath